CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
LY3451838 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04498910
NCT04498910Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine

Eli Lilly and Company·interventional·Posted Aug 5, 2020·Updated Nov 28, 2023

In Brief

A Phase 2 clinical trial evaluating LY3451838 and Placebo for Migraine. Completed, enrolled 38 participants across 9 sites.

Detailed Summary

The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 5, 2020
Enrollment StartNov 16, 2020
Primary CompletionNov 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.9 years ago

Interventions

LY3451838drug

Administered IV

Placebodrug

Administered IV